F S&P 500
5,442.50 +5.00 (+0.09%) F Dow Jones
38,625.00 +20.00 (+0.05%) F Nasdaq
19,719.00 +33.50 (+0.17%) E-mini Russell 2000 Index Futur
2,012.60 +4.60 (+0.23%) Petróleo
78.37 -0.08 (-0.10%) Oro
2,332.30 -16.80 (-0.72%)
Ascelia Pharma AB (publ) (ACE.ST)
Ascelia Pharma AB (publ)
Hyllie Boulevard 34
Malmö 215 32
Sweden
46 7 35 17 91 18
https://www.ascelia.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 13
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Magnus O. Corfitzen | Chief Executive Officer | 3.41M | N/D | 1975 |
| Mr. Andreas Norlin | Chief Scientific Officer | N/D | N/D | 1970 |
| Mr. Mikael Widell | Head of IR & Communications | N/D | N/D | 1958 |
| Ms. Julie Waras Brogren | Deputy CEO & Chief Commercial Officer | N/D | N/D | 1972 |
| Ms. Carin Linde | VP of Pharmaceutical Development, Supply & IT | N/D | N/D | 1972 |
Descripción
Ascelia Pharma AB (publ), a biotech company, focuses on orphan oncology treatments in Sweden. The company identifies, develops, and commercializes novel drugs to address unmet needs for rare cancer conditions. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 trial for the treatment of gastric cancer. Ascelia Pharma AB (publ) was incorporated in 1999 and is based in Malmö, Sweden.
Gestión corporativa
La calificación ISS Governance QuickScore de Ascelia Pharma AB (publ) a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
